Anixa Biosciences Inc
About Anixa Biosciences Inc
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $210.0K
- Net income
- -$10.9M
- Total assets
- $16.1M
- Market cap
- $83.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating income
- -$11.7M
- Net income
- -$11.0M
- EPS (basic)
- $-0.34
- EPS (diluted)
- $-0.34
Balance sheet
- Total assets
- $16.1M
- Current assets
- $15.9M
- Total liabilities
- $2.1M
- Current liabilities
- $2.0M
- Shareholders’ equity
- $13.9M
Cash flow
- Operating cash flow
- -$7.2M
- Investing cash flow
- $4.9M
- Financing cash flow
- $2.3M
- Net cash flow
- -$27.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $83.1M
- EPS (diluted)
- $-0.34
- Shares outstanding
- 35.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 7, 1983
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $10.9M in FY2024.
- Trading 55% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Anixa Biosciences Inc.
Write a review
News about Anixa Biosciences Inc
News & sentiment via Polygon.io
